Traditionally heparin has been the anticoagulant of choice for venous dialysis catheter locking. There is systemic leakage of heparin catheter locking solutions at the time of injection. Alternative agents, such as citrate, are increasingly being used. We are not aware of any data in the critical care literature on the effect of citrate locking of venous dialysis catheters on systemic ionised calcium (iCa 2+ 
A prospective observational study of the change in systemic ionised calcium following 4% citrate locking of venous haemodialysis catheters in intensive care patients 
Summary
Traditionally heparin has been the anticoagulant of choice for venous dialysis catheter locking. There is systemic leakage of heparin catheter locking solutions at the time of injection. Alternative agents, such as citrate, are increasingly being used. We are not aware of any data in the critical care literature on the effect of citrate locking of venous dialysis catheters on systemic ionised calcium (iCa 2+ ). To assess the effect of 4% citrate locking of venous dialysis catheters on systemic iCa 2+ in intensive care patients we performed a prospective observational study of 50 paired samples in 26 intensive care patients receiving 4% citrate dialysis catheter locking in an adult tertiary intensive care unit between May 2016 and December 2016. Arterial blood gas (ABG) analysis was performed prior to venous dialysis catheter locking and a baseline iCa 2+ The incidence of acute kidney injury is estimated to be around 20% to 50% in patients admitted to the intensive care unit (ICU) 1 . Approximately 5% of these patients will require extracorporeal renal replacement therapy which is associated with a mortality of 50% to 60% 2 . Venous catheters are the preferred vascular access method for acute kidney injury patients requiring renal replacement therapy 3 and in critical care, non-tunnelled catheters represent standard practice 3, 4 . These catheters carry a risk of catheter thrombosis and/or infection. Catheter-locking solutions are routinely used to prevent such complications.
Traditionally heparin has been the anticoagulant of choice for venous dialysis catheter locking in the interdialytic period. However, heparin is not without shortcomings: 1) there is demonstrable leak of heparin locking solution into the systemic circulation with unintentional systemic anticoagulation [5] [6] [7] [8] and potential major bleeding 9 , 2) heparininduced antibodies may develop, predisposing these patients to the potential risk of heparin-induced thrombocytopenia 10 and 3) heparin can stimulate biofilm formation increasing the risk of catheter infection 11 . Citrate is an alternative to heparin as a catheter-locking solution. Citrate exerts its anticoagulant activity by chelating calcium ions (iCa 2+ ) present in blood, resulting in the blockade of calcium-dependent clotting pathways and a reduction in fibrin formation.
In addition, citrate has been reported to prevent biofilm production 11 , reduce catheter-related bloodstream infection 12, 13 , reduce bleeding complications 14 , and have a pharmaco-economic benefit 14 , when compared to heparin. At our institution, following the demonstration of systemic anticoagulation with concentrated heparin locking solution 5 , we changed practice to use a 4% citrate with taurolidine locking solution. Commonly used citrate locking solutions range from 4% to 46.7%. Systemic leak of citrate may potentially cause ionised hypocalcaemia. With highconcentration citrate locking solutions there have been reported deaths, resulting in the United States Food and Drug Administration issuing a warning to stop using the 46.7% (triCitrasol®, Citra Labs, Braintree, MA, USA) citrate solution for this purpose 15, 16 . High-concentration citrate solutions have also been associated with embolic complications 17 . The use of 4% citrate as a locking solution for venous dialysis catheters is consistent with the American Society of Diagnostic and Interventional Nephrology guideline 18 as well as the European Best Renal Practice guideline 19 . We are not aware of any studies published in the literature systematically assessing the effect of citrate locking on systemic ionised calcium. We undertook a prospective observational study to assess whether locking venous dialysis catheters using 4% citrate solution at the catheter manufacturer's recommended volume resulted in a systemic effect on ionised calcium. We hypothesised that the use of 4% citrate locking solution does not result in a reduction in plasma ionised calcium.
Methods
This prospective observational study was conducted in an adult tertiary ICU at the Princess Alexandra Hospital, Woolloongabba, Queensland. Our study was approved by the Metro South Human Research Ethics Committee (HREC reference number: HREC/15/QPAH/365). The study was performed over a period of eight months from May 2016 to December 2016.
Patients with new or pre-existing venous dialysis catheters requiring anticoagulant locking solution injected into the catheter as part of routine venous dialysis catheter care were included in the study. Patients who were known to have hypersensitivity to citrate and/or (cyclo)-taurolidine were excluded from the study (there were none). As it was a convenience sample we did not exclude patients with hypocalcaemia and/or hypokalaemia.
The type of dialysis catheters used were at the discretion of the treating intensivist. Venous dialysis catheters were routinely inserted under ultrasound guidance with strict aseptic technique and maximal sterile barrier precautions in accordance with the Australian and New Zealand Intensive Care Society Central Line Insertion and Maintenance Guideline 20 . Five millilitre ampoules of TauroLock™ (TauroImplant GmbH, Germany) locking solution containing 4% citrate and 1.35% (cyclo)-taurolidine were routinely used. The locking solution volume used was per the catheter manufacturer's recommendation. Citrate locking procedures were routinely performed by the bedside nurse according to unit guidelines, which involved the required volume for each lumen to be drawn into separate 3 ml syringes and checked by a second nurse prior to administration. Immediately after the patient was disconnected from the dialysis circuit each catheter lumen would be flushed with 10 ml 0.9% saline followed by injection of the locking solution. The second nurse would perform the arterial blood gas (ABG) sampling.
A baseline iCa 2+ was obtained via ABG analysis. After running this blood test, the nurse would go on to immediately cease dialysis and administer the citrate locking solution into the venous dialysis catheter. An arterial blood sample for iCa 2+ measurement was collected between 30 and 120 seconds after locking the catheter with the citrate solution. The decision to take blood samples between 30 and 120 seconds after locking was based upon data regarding circulation time 21 . Pre-and post-citrate locking iCa 2+ values were collected for data analysis. Adverse effects were considered likely to be secondary to a bolus effect and transient, as citrate is rapidly distributed to the extracellular space and metabolised by the liver 22 , with the bolus effect likely to have passed within two minutes. Thirty seconds was considered to be the shortest time reasonable for sample collection with optimal aseptic technique of the venous dialysis catheter and arterial lines.
The potential leak of citrate solution into the systemic circulation following catheter locking could result in ionised hypocalcaemia manifesting clinically with paraesthesia, tetany, dysrhythmias, and/or hypotension. Nursing staff administering the citrate locking solution were directed according to the data collection sheet to observe the bedside monitor during administration and for up to one minute postadministration for arrhythmias, or a change in arterial blood pressure, and to ask awake non-intubated patients if they felt an altered sensation in their mouth or muscle cramps postadministration.
Baseline characteristics of the patients enrolled were collected, including age, sex, weight, catheter type, catheter length, catheter site, total volume of locking solution injected per dialysis catheter and dialysis circuit anticoagulation prior to catheter locking.
A convenience sample of 50 paired results was included. Repeat sampling from the same patient was allowed.
Statistical analysis
The change in iCa 2+ concentrations was modelled using a linear mixed model with a random-intercept at a patient level via restricted maximum likelihood. Changes in iCa 2+ concentrations by subgroups (length of catheter, site of catheter insertion and dialysis circuit anticoagulation) were examined, fitting subgroup as a fixed effect in a linear mixed model with random intercepts.
The level of statistical significance was set at 0.05. P-values were not adjusted for multiple testing.
Stata 15 was used for data analyses.
Results
A total of 50 paired results from 26 patients was collected. The baseline characteristics of the patients (n=26) are shown in Table 1 .
The most commonly inserted venous dialysis catheters in our ICU were the Baxter GAMCATH HighFlow Dolphin Catheters (Baxter, Toongabbie, New South Wales), 13 Frenchgauge double lumen, with catheter access lengths of either 150 mm or 200 mm. Sites of insertion routinely used were the internal jugular and femoral veins. Forty-eight (96%) of the venous dialysis catheters were non-tunnelled (45 were Baxter GAMCATH HighFlow Dolphin Catheters, two were ARROWg+ard® catheters [Teleflex Medical, Morrisville, NC, USA], and one was a Power-Trialysis® catheter [Bard Access Systems, Salt Lake City, UT, USA]). The remaining two were tunnelled dialysis catheters (we were unable to ascertain further information, including the brand, for these catheters).
Characteristics of dialysis at each paired measurement (n=50) are shown in Table 2 .
The pre-catheter locking iCa 2+ concentration and the change in iCa 2+ concentration (mmol/l) are summarised overall and by subgroups in Table 3 .
On average, there was little difference between the preand post-catheter locking iCa 2+ concentration (median pre 1.19 mmol/l; mean change of +0.004 mmol/l (95% confidence interval [CI] -0.004 to 0.013, P=0.34).
The change in iCa 2+ concentration did not differ between patients with different lengths of dialysis catheters (150 mm versus 200 mm) (P=0.26), or between patients who had a catheter inserted at different sites (femoral versus internal jugular) (P=0.85).
The change in iCa 2+ concentration was found to be significantly different between patients who received citrate dialysis circuit anticoagulation and those who did not (P=0.013). Patients who received citrate dialysis circuit anticoagulation had an increased catheter locking iCa 2+ by 0.017 (95% CI 0.005 to 0.028) mmol/l whereas there was no significant change in catheter locking iCa 2+ within patients who did not receive citrate dialysis circuit anticoagulation.
There were no clinical adverse effects reported.
Discussion
In our study of 50 paired samples there was no significant change in the iCa 2+ concentration, nor any adverse events, following bolus injection of 4% citrate catheter locking solution into predominantly non-tunnelled venous dialysis catheters. Interestingly, there was a statistically significant, though likely clinically insignificant, increase in iCa 2+ in the group of patients who were receiving citrate dialysis circuit anticoagulation prior to catheter locking. When citrate dialysis circuit anticoagulation is utilised in our ICU the calcium infusion is controlled by the dialysis machine and is therefore ceased at the same time that dialysis is ceased in our patient cohort. Possible reasons for the rise in iCa 2+ concentration include: 1) a chance finding given multiple statistical assessments of the data, or 2) metabolism of citrate with liberation of the chelated calcium increasing systemic iCa 2+ concentration. During citrate dialysis circuit anticoagulation, citrate is used pre-filter to chelate calcium ions. The majority of calcium citrate product is removed by the dialysis, but a proportion of the calcium citrate product is not removed by the filter and enters the systemic circulation. During dialysis a steady state of calcium citrate product in the blood will be reached, being a balance between infused citrate and citrate metabolised by the liver. When dialysis is ceased, the ongoing metabolism of calcium citrate product releases chelated calcium ions into the systemic circulation, thus potentially leading to a rise in ionised calcium levels, as seen in our study.
Citrate concentrations of 23%, 30% and 47% are considerably denser than blood and this causes some of the citrate to leak out of the catheter immediately after the locking procedure 23 . In the studies by Ash et al 24 and Weijmer et al 12 , when catheters were locked with 30% or 47% citrate, some patients reported a metallic taste and paraesthesia of their fingers or lips. These side-effects were attributed to the appearance of citrate in the bloodstream causing transient ionised hypocalcaemia, and suggest that these concentrations of citrate may lead to clinically significant hypocalcaemia.
With the use of 4% citrate as a catheter locking solution, it has been reported that there was a 50-to 100-fold margin of safety when catheters were locked appropriately 25 . Our study sought to determine if venous dialysis catheter locking with low-concentration citrate resulted in a systemic effect on iCa 2+ or led to any transient symptoms. Our findings were consistent with the reported safety of 4% citrate locking solutions.
The strength of our study is that all locking of catheters was performed using a standard protocol with the manufacturerrecommended volume of solution, reflecting real world practice.
The limitations to our study are: 1) the sample size was small, 2) repeat sampling was allowed from the same patient, 3) we may have missed the bolus effect of the citrate (the time for normal circulation in non-critically unwell patients ranges from 15 to 40 seconds following injection of contrast media) 21 , and 4) a range of catheter types and positions were sampled in patients receiving citrate dialysis circuit anticoagulation as well as conventional dialysis methods, introducing heterogeneity.
Conclusions
Locking of venous dialysis catheters with 4% citrate solution has no clinically significant effect on systemic iCa 2+ in intensive care patients undergoing dialysis. We detected a statistically significant, but clinically insignificant, rise in iCa 2+ in patients who were dialysed with citrate dialysis circuit anticoagulation prior to catheter locking. This is considered to be unrelated to the citrate locking of the venous dialysis catheter.
